Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Methodological standard · §6

CEI-MS-13 — worked example

A worked calculation, and an illustrative mass balance showing what a purity figure alone does not establish.

Document identifier
CEI-MS-13/6
Series
Methodological standard
Version
1.2
Published
21 Feb 2025
Last reviewed
21 Aug 2025
Next review
21 Aug 2028
Identifier
10.71829/cei.meth.12
Certainty
High
Cycle
2025 Q1
Category
Method validation

§6Worked example

§6.1Worked example — mass balance on an oxidative challenge

  1. A peptide containing two methionine residues is stressed with 0.3 % hydrogen peroxide for 4 hours at 25 °C. Unstressed total area 5 002 100 µV·s with the main peak at 4 921 000 µV·s (98.4 %).
  2. After stress: main peak 4 016 400 µV·s; a new peak at shorter retention 612 300 µV·s, identified by LC–MS as the mono-sulfoxide (+16 Da); a second new peak 214 800 µV·s identified as the bis-sulfoxide (+32 Da).
  3. Degradation achieved = (4 921 000 − 4 016 400) ÷ 4 921 000 = 18.4 %, within the 5–20 % window.
  4. Mass balance = (4 016 400 + 612 300 + 214 800 + other unchanged impurities 81 100) ÷ 5 002 100 = 4 924 600 ÷ 5 002 100 = 98.4 %.
  5. The balance closes at 98.4 %, within the 95–105 % criterion, and both degradants are resolved from the analyte at R > 1.5. The method sees the degradation chemistry this peptide actually undergoes and can therefore support a purity claim over time.
  6. Had the same method been validated against acid and base stress only, it would have been declared stability-indicating without ever having been shown to resolve the sulfoxides — which are, for this sequence, the only degradants that matter.

§6.2Illustrative mass balance

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute
  2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.